Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.03 | -2.9702970297 | 1.01 | 1.08 | 0.8 | 238193 | 0.95556925 | CS |
| 4 | -0.21 | -17.6470588235 | 1.19 | 1.22 | 0.8 | 220315 | 1.06615582 | CS |
| 12 | -0.15 | -13.2743362832 | 1.13 | 1.5 | 0.8 | 319200 | 1.16744582 | CS |
| 26 | -0.61 | -38.3647798742 | 1.59 | 2.5591 | 0.8 | 923890 | 1.5464467 | CS |
| 52 | 0.0394 | 4.18881564959 | 0.9406 | 5.01 | 0.51 | 2031719 | 2.85822964 | CS |
| 156 | -6.02 | -86 | 7 | 7.9799 | 0.51 | 1342267 | 2.85870412 | CS |
| 260 | -6.02 | -86 | 7 | 7.9799 | 0.51 | 1342267 | 2.85870412 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
